Last updated on February 2018

Post-Authorisation Study on the Use of Bemfola in Human Assisted Reproductive Technology

Brief description of study

Prospective, non-comparative, multi-centre, multi-country, observational post-authorization study, to correlate predictive factors with number of oocytes in relation to the gonadotropin dose administered using a new r-hFSH product (Bemfola) for ovarian stimulation and GnRH-antagonists for pituitary suppression

Detailed Study Description

This will be a prospective, non-comparative, multi-centre, multi-country, observational post-authorization study in Germany and Austria. The study will evaluate the use of follitropin alfa (Bemfola) in controlled ovarian stimulation for IVF/ICSI.

About 30 ART centres will be involved in the study. Upon site initiation, each investigator site will enrol the subjects who meet the inclusion criteria.

As this is an observational study, there will be no additional treatment or diagnostic procedures performed on subjects other than those of the investigators' local routine clinical practice. The decision to start ART treatment and to use Bemfola in controlled ovarian hyperstimulation (COH) following a GnRH antagonist protocol will be made independently by the investigators as per the ART centre's protocol, preceding patient enrollment for this study.

Clinical Study Identifier: NCT02942849

Contact Investigators or Research Sites near you

Start Over

Gerhard Pohlig, MD

Team Kinderwunsch Oldenburg
Oldenburg, Germany
  Connect »